CME Presentations
Atopic Dermatitis in the AA Community and Beyond
Presentations
Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations
Speakers: Andrew Alexis, MD, MPH, Professor of Clinical DermatologyJonathan I. Silverberg, MD, PhD, MPH, Professor, Director of Clinical Research, Director of Patch TestingRaelle Brown Duration: 60 minutes
Presented on: October 25, 2022
Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library
Speakers: Andrew Alexis, MD, MPH, Professor of Clinical DermatologyJonathan I. Silverberg, MD, PhD, MPH, Professor, Director of Clinical Research, Director of Patch Testing Duration: 60 minutes
Presented on: October 25, 2022
Speakers
CME Information
Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.DATE OF RELEASE/EXPIRATION
This activity was released on October 24, 2022 and is valid until October 24, 2023. Requests for credit must be made no later than October 24, 2023TARGET AUDIENCE
The target audiences for the proposed HCP activity are allergists, dermatologists, immunologists, specialty NPs and PAs,STATEMENT OF NEED/PROGRAM OVERVIEW
People from racially and ethnically diverse populations with moderate-to-severe atopic dermatitis (AD) face socioeconomic and care inequities that impair their access to optimal care for AD and its comorbidities. In addition, topical corticosteroids and unapproved immunosuppressants are often relied upon to treat moderate-to-severe AD, delaying the evidence-based use of more-effective targeted treatments.
Join a panel of diverse allergy and dermatology specialists, patients, and representatives from the Asthma and Allergy Foundation of America (AAFA) for a series of CME activities designed to share strategies that maintain long-term control across the lifespan of AD, from pediatric to adulthood, while ensuring access and care equity for diverse racial and ethnic patient populations. Expert panelists will address gaps in therapy initiation and long-term efficacy and safety, while reviewing experiences with current therapies for moderate-to-severe AD. The education will also emphasize the systemic and T2-driven nature of AD, along with the need for multidisciplinary care.
Session 1, “Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations,” will highlight the unique challenges that people from diverse racial and ethnic groups face when attempting to access care, obtain a diagnosis, and receive holistic care that addresses AD and any associated comorbidities.
Session 2, “Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library,” will guide clinicians to align therapeutic decisions to clinical endophenotypes in patients of different age groups and races. Panelists will also review evidence-based treatment recommendations to achieve long-term disease control, along with strategies to encourage shared decision-making with patients.
Do you have patients who could benefit from related education on the recognition and treatment of AD? Direct your patients to MedLive.com to access the patient-education activity, “It Isn’t Just Skin: The Ins and Outs of Moderate-to-Severe Atopic Dermatitis.”EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Drawing from examples in other diseases, such as asthma, summarize strategies to enhance access to AD care for people from diverse populations.
- Summarize the impacts of age, race, and ethnicity on the presentation of AD and the influence of underlying inflammatory pathways on therapeutic decisions
- Engage patients with moderate-to-severe AD and their caregivers in shared decision-making to set treatment expectations, define success, and make timely therapeutic changes to facilitate long-term remission
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 75 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Dr. Jonathan Silverberg MD, PhD, MPH
Professor, Director of Clinical Research, Director of Patch Testing
George Washington University
School of Medicine and Health Sciences
Washington, District of ColumbiaConsulting Fee: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union
Speakers’ Bureau: AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme
Contracted Research (grants to institution): Galderma, Pfizer
Stock Shareholder: Arcutis, Eli Lilly, PfizerDr. Andrew Alexis, M.D. MPH
Vice-Chair for Diversity and Inclusion
Department of Dermatology
Professor of Clinical Dermatology
Weill Cornell Medical College, Cornell UniversityConsulting Fee: AbbVie, Allergan, Almirall, Amgen, Arcutis, Bausch Health, Beiersdorf, Bristol-Myers Squibb, Cutera, Dermavant, Eli Lilly, Galderma, Janssen, Leo, L’Oreal, Ortho, Pfizer, Sanofi-Regeneron, Sol-Gel, Swiss American, UCB, VisualDx, Vyne
Contracted Research (funds to institution): AbbVie, Almirall, Amgen, Arcutis, Bristol-Myers-Squibb, Cara, Castle, Dermavant, Galderma, Leo, Novartis, Valeant (Bausch Health), Vyne
Speakers’ Bureau: Bristol-Myers Squibb, Pfizer, Regeneron, Sanofi-GenzymeSanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of AmericaNothing to disclose Christopher Aviles
Adult with severe eczemaNothing to disclose
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Carole Drexel Nothing to disclose Lauren Sinclair Nothing to disclose Eve Wilson Nothing to disclose Caroline Laurendeau Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.DATE OF RELEASE/EXPIRATION
This activity was released on October 24, 2022 and is valid until October 24, 2023. Requests for credit must be made no later than October 24, 2023TARGET AUDIENCE
The target audiences for the proposed HCP activity are allergists, dermatologists, immunologists, specialty NPs and PAs,STATEMENT OF NEED/PROGRAM OVERVIEW
People from racially and ethnically diverse populations with moderate-to-severe atopic dermatitis (AD) face socioeconomic and care inequities that impair their access to optimal care for AD and its comorbidities. In addition, topical corticosteroids and unapproved immunosuppressants are often relied upon to treat moderate-to-severe AD, delaying the evidence-based use of more-effective targeted treatments.
Join a panel of diverse allergy and dermatology specialists, patients, and representatives from the Asthma and Allergy Foundation of America (AAFA) for a series of CME activities designed to share strategies that maintain long-term control across the lifespan of AD, from pediatric to adulthood, while ensuring access and care equity for diverse racial and ethnic patient populations. Expert panelists will address gaps in therapy initiation and long-term efficacy and safety, while reviewing experiences with current therapies for moderate-to-severe AD. The education will also emphasize the systemic and T2-driven nature of AD, along with the need for multidisciplinary care.
Session 1, “Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations,” will highlight the unique challenges that people from diverse racial and ethnic groups face when attempting to access care, obtain a diagnosis, and receive holistic care that addresses AD and any associated comorbidities.
Session 2, “Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library,” will guide clinicians to align therapeutic decisions to clinical endophenotypes in patients of different age groups and races. Panelists will also review evidence-based treatment recommendations to achieve long-term disease control, along with strategies to encourage shared decision-making with patients.
Do you have patients who could benefit from related education on the recognition and treatment of AD? Direct your patients to MedLive.com to access the patient-education activity, “It Isn’t Just Skin: The Ins and Outs of Moderate-to-Severe Atopic Dermatitis.”EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Drawing from examples in other diseases, such as asthma, summarize strategies to enhance access to AD care for people from diverse populations.
- Summarize the impacts of age, race, and ethnicity on the presentation of AD and the influence of underlying inflammatory pathways on therapeutic decisions
- Engage patients with moderate-to-severe AD and their caregivers in shared decision-making to set treatment expectations, define success, and make timely therapeutic changes to facilitate long-term remission
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Dr. Jonathan Silverberg MD, PhD, MPH
Professor, Director of Clinical Research, Director of Patch Testing
George Washington University
School of Medicine and Health Sciences
Washington, District of ColumbiaConsulting Fee: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union
Speakers’ Bureau: AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme
Contracted Research (grants to institution): Galderma, Pfizer
Stock Shareholder: Arcutis, Eli Lilly, PfizerDr. Andrew Alexis, M.D. MPH
Vice-Chair for Diversity and Inclusion
Department of Dermatology
Professor of Clinical Dermatology
Weill Cornell Medical College, Cornell UniversityConsulting Fee: AbbVie, Allergan, Almirall, Amgen, Arcutis, Bausch Health, Beiersdorf, Bristol-Myers Squibb, Cutera, Dermavant, Eli Lilly, Galderma, Janssen, Leo, L’Oreal, Ortho, Pfizer, Sanofi-Regeneron, Sol-Gel, Swiss American, UCB, VisualDx, Vyne
Contracted Research (funds to institution): AbbVie, Almirall, Amgen, Arcutis, Bristol-Myers-Squibb, Cara, Castle, Dermavant, Galderma, Leo, Novartis, Valeant (Bausch Health), Vyne
Speakers’ Bureau: Bristol-Myers Squibb, Pfizer, Regeneron, Sanofi-GenzymeSanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of AmericaNothing to disclose Raelle Brown
Patient ParticipantNothing to disclose
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Carole Drexel Nothing to disclose Lauren Sinclair Nothing to disclose Eve Wilson Nothing to disclose Caroline Laurendeau Nothing to disclose Lynell Doyle- Parent of child with Eczema Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.